HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: These mainly include PKC agonists, atypical NF-κB agonists, and HDAC inhibitors (HDACis).27 The regulation of HDAC activity on the HIV long terminal repeat (LTR) promoter has been extensively documented as critical for enhancing HIV expression.28,29 Chidamide, a HDAC inhibitor in the benzamide category, is specifically designed for oral administration to inhibit HDAC1, 2, 3, and 10 selectively and was approved by the China Food and Drug Administration (CFDA) in December 2014 for treating relapsed or refractory PTCL.